Nigeria planned to control majority of the multi-billion U.S. dollar pharmaceutical market in Africa, an official with the National Institute for Pharmaceutical Research and Development (NIPRD) has said.
While speaking to reporters in Abuja, Nigeria’s capital, on Tuesday, Obi Adigwe, director general of NIPRD, said Nigeria was endowed with good climatic conditions and numerous natural plants that could translate into medicinal and economic values.
He told his audience that the institute had already developed several pharmaceutical products that would impact positively on the health sector when they got to the market.
According to him, NIPRD is supposed to be the hub of all research that relate to pharma, food, commodities and development of natural resources that will bring out products that will impact on Africa’s healthcare.
Nigeria is richly blessed with considerable amount of plants that have ethno-medicinal and ethno-pharmaceutical properties, he added, noting that the country also has different climatic zones that provide unique condition for the growth of high quality plants.
“We at NIPRD already have about eight different, fully developed products and about 23 on the pipeline; products for treating malaria, diabetes, tuberculosis, and for dermatitis,” said the expert.
The institute was also collaborating with some Nigerian universities for greater impact in the field of pharmacy, said the director general.
He added that NIPRD was also consolidating its partnership with some state governments to tap into their natural endowments for health and economic advancement.
A Contextual Processing Protocol (CPP) had been developed to create ease for harnessing natural resources across the country, Adigwe said.
The director told reporters that the institute is working to ensure that Nigeria’s pharmaceutical sector drives socio-economic development in the country.
However, Adigwe clarified that NIPRD was confronting the challenge of making its pharmaceutical products available to Nigerians, adding that there is still a bit of work to be done to get to the stage where people will walk to the stores and buy our products.
“Our biggest challenge is funding and we have started reaching out to some partners and potential investors, foundations and development bodies that can help to push the products along,” the director told reporters. Enditem